Innocoll Holdings PLC (NASDAQ: INNL) and SciClone Pharmaceuticals (NASDAQ:SCLN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk.
Insider and Institutional Ownership
34.2% of Innocoll Holdings PLC shares are owned by institutional investors. Comparatively, 72.8% of SciClone Pharmaceuticals shares are owned by institutional investors. 5.2% of SciClone Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Innocoll Holdings PLC and SciClone Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Innocoll Holdings PLC||N/A||N/A||N/A||($1.67)||-1.41|
|SciClone Pharmaceuticals||$172.02 million||3.38||$45.42 million||$0.82||13.60|
SciClone Pharmaceuticals has higher revenue and earnings than Innocoll Holdings PLC. Innocoll Holdings PLC is trading at a lower price-to-earnings ratio than SciClone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent ratings and target prices for Innocoll Holdings PLC and SciClone Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Innocoll Holdings PLC||0||3||1||0||2.25|
Innocoll Holdings PLC presently has a consensus target price of $4.50, indicating a potential upside of 91.49%. SciClone Pharmaceuticals has a consensus target price of $14.00, indicating a potential upside of 25.56%. Given Innocoll Holdings PLC’s stronger consensus rating and higher possible upside, research analysts plainly believe Innocoll Holdings PLC is more favorable than SciClone Pharmaceuticals.
This table compares Innocoll Holdings PLC and SciClone Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Innocoll Holdings PLC||-1,051.20%||N/A||-138.53%|
Risk and Volatility
Innocoll Holdings PLC has a beta of -0.3, meaning that its stock price is 130% less volatile than the S&P 500. Comparatively, SciClone Pharmaceuticals has a beta of 1.72, meaning that its stock price is 72% more volatile than the S&P 500.
SciClone Pharmaceuticals beats Innocoll Holdings PLC on 8 of the 11 factors compared between the two stocks.
Innocoll Holdings PLC Company Profile
Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically. Using its processes at its manufacturing facility, it derives and purifies bovine and equine collagen and then utilizes its technology platform to incorporate the purified collagen into its topical and implantable products. Its lead product candidates are XaraColl for the treatment of post-operative pain and Cogenzia for the treatment of diabetic foot infections. Its marketed products include CollaGUARD, Collatamp, Septocoll and RegenePro. It has initiated its Phase III efficacy trials for Cogenzia.
SciClone Pharmaceuticals Company Profile
SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company’s lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL). Its development portfolio includes Angiomax, Loramyc, Neucardin, VIBATIV and Cleviprex.
Receive News & Ratings for Innocoll Holdings PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innocoll Holdings PLC and related companies with MarketBeat.com's FREE daily email newsletter.